Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50–64 years of age

Highlights • A high-dose inactivated influenza vaccine (IIV-HD) is available for adults ≥65years. • IIV-HD and a standard-dose vaccine (IIV-SD) were evaluated in adults 50–64 years. • Immune responses were generally stronger for the IIV-HD. • Reactogenicity was higher for IIV-HD, but it was well tol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-12, Vol.33 (51), p.7188-7193
Hauptverfasser:	DiazGranados, Carlos A, Saway, William, Gouaux, James, Baron, Mira, Baker, Jeffrey, Denis, Martine, Jordanov, Emilia, Landolfi, Victoria, Yau, Eddy
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Allergy and Immunology Antibodies, Viral - blood Clinical trial Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Hemagglutination Inhibition Tests Hepatitis Humans Immunogenicity Inactivated Influenza Influenza vaccines Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza Vaccines - immunology Influenza, Human - prevention & control International conferences Male Middle Aged Older people Phase II Safety Single-Blind Method Treatment Outcome Vaccines Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - adverse effects Vaccines, Inactivated - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • A high-dose inactivated influenza vaccine (IIV-HD) is available for adults ≥65years. • IIV-HD and a standard-dose vaccine (IIV-SD) were evaluated in adults 50–64 years. • Immune responses were generally stronger for the IIV-HD. • Reactogenicity was higher for IIV-HD, but it was well tolerated. • IIV-HD may improve immune responses to influenza in adults 50–64 years.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.10.131